Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment

Journal of the National Cancer Institute

Volumn 106, Issue 8, 2014, Pages

  Sadow, Peter M ^a   Priolo, Carmen ^b   Nanni, Simona ^c   Karreth, Florian A ^d   Duquette, Mark ^d   Martinelli, Roberta ^e   Husain, Amjad ^e   Clohessy, John ^d   Kutzner, Heinz ^f   Mentzel, Thomas ^f   Carman, Christopher V ^e   Farsetti, Antonella ^g   Henske, Elizabeth Petri ^b   Palescandolo, Emanuele ^d,h   Macconaill, Laura E ^d,h   Chung, Seum ⁱ   Fadda, Guido ^c   Lombardi, Celestino Pio ^j   De Angelis, Antonina M ^k   Durante, Oreste ^k   Parker, John A ^d   Pontecorvi, Alfredo ^c   Dvorak, Harold F ^e   Fletcher, Christopher ^b   Pandolfi, Pier Paolo ^d   Lawler, Jack ^e   Nucera, Carmelo ^d   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CATHOLIC UNIVERSITY   (Italy)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f Dermatopathologische Gemeinschaftspraxis   (Germany)

^g CNR   (Italy)

^h BROAD INSTITUTE OF MIT AND HARVARD   (United States)

ⁱ National Health Insurance Corporation   (South Korea)

^j CATHOLIC UNIVERSITY   (Italy)

^k UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; B RAF KINASE; BETA1 INTEGRIN; BINDING PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DESMIN; LONG UNTRANSLATED RNA; NEURON GLIAL ANTIGEN 2; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN; PROTEIN P16; UNCLASSIFIED DRUG; VEMURAFENIB; ANGIOGENESIS INHIBITOR; BRAF PROTEIN, HUMAN; GLUTAMIC ACID; INDOLE DERIVATIVE; SULFONAMIDE; TUMOR MARKER; VALINE;

ARTICLE; CANCER GENETICS; CANCER INFILTRATION; CANCER RECURRENCE; CELL ADHESION; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENOME ANALYSIS; GENOTYPE; HEMANGIOPERICYTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIFOCAL INFILTRATING MYOPERICYTOMA; NONHUMAN; PERICYTE; PRIORITY JOURNAL; THYROID TUMOR; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; X CHROMOSOME INACTIVATION; CELL PROLIFERATION; DRUG SCREENING; GENETICS; MASS SPECTROMETRY; MUTATION; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; CELL LINE, TUMOR; CELL PROLIFERATION; GENOTYPE; GLUTAMIC ACID; HEMANGIOPERICYTOMA; HUMANS; INDOLES; MASS SPECTROMETRY; MUTATION; NEOPLASM RECURRENCE, LOCAL; PERICYTES; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VALINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907007265     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju182     Document Type: Article

References (33)

1. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. Fourth Edition. IARC Press, Lyon, France. 2013;5.
2. Mentzel T, Dei Tos AP, Sapi Z, Kutzner H. Myopericytoma of skin and soft tissues: clinicopathologic and immunohistochemical study of 54 cases. AJSP. 2006;30(1):104-113.
3. Diaz-Flores L, Gutierrez R, Garcia MP, Diaz-Flores L, Jr, Valladares F, Madrid JF. Ultrastructure of myopericytoma: a continuum of transitional phenotypes of myopericytes. Ultrastruct Pathol. 2012;36(3):189-194.
4. Fisher C. Unusual myoid, perivascular, and postradiation lesions, with emphasis on atypical vascular lesion, postradiation cutaneous angiosarcoma, myoepithelial tumors, myopericytoma, and perivascular epithelioid cell tumor. Sem Diagn Pathol. 2013;30(1):73-84.
5. McMenamin ME, Fletcher CD. Malignant myopericytoma: expanding the spectrum of tumours with myopericytic differentiation. Histopathol. 2002;41(5):450-460.
6. Matulonis UA, Hirsch M, Palescandolo E, et al. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PloS One. 2011;6(9):e24433.
7. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. AJHG. 1992;51(6):1229-1239.
8. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596-599.
9. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
10. Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11):873-886.
11. Sondergaard JN, Nazarian R, Wang Q, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010;8:39.
12. Dray MS, McCarthy SW, Palmer AA, et al. Myopericytoma: a unifying term for a spectrum of tumours that show overlapping features with myofibroma. A review of 14 cases. J Clin Pathol. 2006;59(1):67-73.
13. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493-1501.
14. Nucera C, Nehs MA, Nagarkatti SS, et al. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011;16(3):296-309.
15. Nucera C, Porrello A, Antonello ZA, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA. 2010;107(23):10649-10654.
16. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev. 2013;13(3):184-199.
17. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013;3(5):520-533.
18. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-2315.
19. Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121(12):4700-4711.
20. Peyrade F, Re D, Ginet C, et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica. 2013;98(2):e20-22.
21. Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013;368(7):684-685.
22. Nehs MA, Nucera C, Nagarkatti SS, et al. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology. 2012;153(2):985-994.
23. Nehs MA, Nagarkatti S, Nucera C, Hodin RA, Parangi S. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery. 2010;148(6):1154-1162; discussion 62
24. Shaik S, Nucera C, Inuzuka H, et al. SCF(beta-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2 J Exp Med. 2012;209(7):1289-1307.
25. Choueiri TK, Cheville J, Palescandolo E, et al. BRAF mutations in metanephric adenoma of the kidney. Eur Urol. 2012;62(5):917-922.
26. Rosty C, Buchanan DD, Walters RJ, et al. Hyperplastic polyp of the duodenum: a report of 9 cases with immunohistochemical and molecular findings. Hum Pathol. 2011;42(12):1953-1959.
27. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF(E600) in benign and malignant human tumours. Oncogene. 2008;27(7):877-895.
28. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
29. Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014;46(2):161-165.
30. Franco M, Roswall P, Cortez E, Hanahan D, Pietras K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood. 2011;118(10):2906-2917.
31. Jain RK, Booth MF. What brings pericytes to tumor vessels? J Clin Invest. 2003;112(8):1134-1136.
32. Whelan MC, Senger DR. Collagen I initiates endothelial cell morphogenesis by inducing actin polymerization through suppression of cyclic AMP and protein kinase A. JBC. 2003;278(1):327-334.
33. Lasorella A, Rothschild G, Yokota Y, Russell RG, Iavarone A. Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice. MCB. 2005;25(9):3563-3574.